Core Viewpoint - The OTC channel presents significant opportunities for beauty brands, offering professional endorsements, precise targeting of skincare needs, and immediate product experiences, but it also poses challenges due to strict professional requirements and a talent shortage in the industry [1][2][3]. Group 1: Market Entry and Growth - By 2025, over six domestic cosmetic companies are expected to enter the OTC channel, marking it as the "Year of Domestic Beauty OTC Layout" [2]. - Leading domestic beauty brand Proya (603605.SH) announced its entry into the OTC channel in January 2026, joining a growing list of companies [2]. - Brands like Winona and Kefu Beauty have been early entrants into the OTC channel, with Winona's sales nearing 1 billion yuan in 2023, capturing over 60% of the market share in this channel [5]. Group 2: Strategic Developments - In April 2025, Furuida Bio announced plans to accelerate its OTC channel development, aiming to cover 10,000 drugstore chains and launch 100 "cosmetic and medicinal" SKUs [5]. - Companies are increasingly focusing on integrating with the professional environment of pharmacies rather than merely distributing products [5]. - Proya is preparing multiple products for the OTC channel, emphasizing the importance of medical device products as a foundation for entry [6]. Group 3: Market Potential and Challenges - The OTC channel has approximately double the growth potential, with Winona targeting to cover 250,000 pharmacies [8]. - As of December 2024, there are about 705,000 licensed drug retail enterprises in China, with Winona covering over 110,000, representing about one-seventh of the total retail pharmacy stores [9]. - The demand for beauty products in pharmacies is rising due to pressures on traditional pharmacy profits and the need for transformation [9]. Group 4: Profitability and Talent Shortage - Medical device products have a significantly higher gross margin, averaging 77%-83%, compared to regular cosmetic products [9]. - The beauty industry faces a talent shortage in the pharmacy channel, as many brands rely on pharmacists who must understand both pharmaceuticals and cosmetics [10]. - Companies like Betaini are addressing this by training pharmacy staff to enhance customer trust and provide professional consultations [10][11].

Core Insights - The article discusses the growing trend of domestic beauty brands entering the OTC (over-the-counter) channel in China, with 2025 being marked as a pivotal year for this transition [2][3] - Major players like Proya and other beauty companies are preparing to launch products in the OTC space, which is seen as a way to leverage the professional credibility of pharmacies and meet specific skincare needs [4][5] Group 1: Market Entry and Growth - By 2025, over six domestic cosmetic companies are expected to enter the OTC channel, expanding the current limited presence of leading brands [2] - Proya announced its entry into the OTC channel in January 2026, joining other brands that have already established a presence [2][4] - The OTC channel has seen significant sales, with brands like Winona achieving nearly 1 billion yuan in sales from this channel in 2023 [3] Group 2: Strategic Partnerships and Product Development - Companies are focusing on strategic partnerships and product development tailored for the OTC market, with Proya preparing multiple products aimed at post-operative recovery and daily skincare [4] - Winona and other brands are actively seeking to enhance their product offerings and market reach through collaborations with pharmacies [3][4] Group 3: Market Potential and Challenges - The OTC channel is projected to have about double the growth potential, with Winona aiming to cover 250,000 pharmacies [5] - The regulatory environment is becoming more favorable for pharmacies to sell cosmetic products, which aligns with the increasing demand for beauty products in these settings [6] - Despite the opportunities, there is a significant talent shortage in the OTC channel, as brands require personnel who are knowledgeable in both pharmaceuticals and cosmetics [7] Group 4: Financial Metrics and Profitability - The average gross margin for medical beauty products in the OTC channel is significantly higher than that of regular cosmetic products, with margins for medical dressings ranging from 77% to 83% [6] - Specific companies report high gross margins, such as 84.22% for Chuerjia's medical device products and 82% for Jinjian Biological's collagen products [6]

Core Viewpoint - The article highlights the competitive landscape of the beauty industry during the Double 11 shopping festival, focusing on Proya's strong performance and strategic moves towards international expansion through a Hong Kong IPO. Group 1: Company Performance - Proya's products, including the Double Anti-Aging Essence and Ruby Cream, achieved over 100 million yuan in sales within the first 6 minutes of the Double 11 event [2] - Proya maintained its position as the top seller in the beauty category on Tmall, showcasing its strong brand presence [3] - The company's main brand revenue for the first half of the year was 3.979 billion yuan, a slight decline of 0.08%, marking the first drop in five years [8] Group 2: Product Strategy - Proya has developed a product line centered around the "Early C (Vitamin C) and Late A (Retinol)" concept, which has been heavily promoted through social media and influencer marketing [4] - The company has bundled its key products, such as the Double Anti-Aging and Ruby Essence, to cater to price-sensitive consumers, with promotional pricing under 300 yuan [5][6] - Despite stable product iterations, Proya has struggled to introduce new blockbuster products, with recent launches not achieving significant sales compared to previous hits [9] Group 3: Management and Strategic Changes - Proya's new CEO, Hou Yamen, faces challenges from increased competition and a lack of new hit products [8] - The company is shifting focus towards medical beauty and men's skincare, launching its first medical-grade product aimed at post-surgery recovery [10] - Proya has made significant management changes, appointing new executives with backgrounds in major international companies to enhance its strategic direction [14][16] Group 4: International Expansion - Proya has announced an investment in the makeup brand Huazhixiao, acquiring a 38.45% stake, and is establishing a European innovation center to accelerate overseas acquisitions [12] - The company aims to become the first beauty brand listed in both A-share and H-share markets, seeking to raise funds for R&D and brand development [17]

中国化妆品行业的历史正式翻开新的篇章！ 4月2 4日晚间，珀莱雅发布的最新年报显示，其2 0 2 4年营收达到1 0 7 . 7 8亿元。刷新了中国本土 化妆品企业的最高营收纪录，也意味着中国本土化妆品企业正式进入百亿时代。 这一里程碑背后，是中国化妆品行业从"渠道为王"到"科研立命"的基因突变。经济学家郑永年 提出，未来1 0年，中国正面临"中等技术陷阱"的挑战——提升"从0到1 "的原创性创新能力， 以及在" 1 - 1 0 "技术刻度上持续升级，是企业博得可持续发展的关键。这一洞察同样适用于本土 美妆市场。 那 么 ， 在 跨 过 百 亿 规 模 之 后 的 未 来 十 年 ， 珀 莱 雅 又 有 哪 些 长 远 目 标 和 规 划 ？ 《 FBe a u t y 未 来 迹》专访珀莱雅首席科学官黄虎，试图从研发的视角探索这家本土美妆企业的战略性布局。 珀莱雅首席科学官 黄虎 据 《 FBe a u t y 未 来 迹 》 了 解 ， 在 跨 越 百 亿 门 槛 之 后 ， 珀 莱 雅 已 经 正 式 定 下 了 " 双 十 " 战 略 愿 景 ——" 未来十年跻身全球化妆品行业前十 "。 回 顾 历 ...